Congress Leans On FDA, NIH To Put More Women In Clinical Trials
This article was originally published in The Gray Sheet
There was a significant focus on putting more women in clinical trials on Capitol Hill on April 30, when 14 female Senators sent a letter to FDA, calling for an action plan to spur greater subgroup, especially female, participation in clinical trials, while a group of 10 Democrats asked GAO to examine what NIH is doing to meet the same goals.
You may also be interested in...
BIO-LIBRA will study Biotronik ICDs and CRT-D devices in about 1,000 patients with non-ischemic cardiomyopathy. The investigators expect at least 40% of the subjects in BIO-LIBRA to be women.
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.